News

The rationale for the study under discussion is that the experience level of the operating surgeon is a potential factor affecting the outcomes of all ophthalmic procedures, including ISBCS

Robyn Guymer, AM, MBBS, PhD, FRANZCO, FAHMS, presented two studies involving the EZ line at this year’s International SPECTRALIS Symposium

Ophthalmologists may be “at the forefront of a revolution in healthcare,” the nephrology professor said at this year’s International SPECTRALIS Symposium

The new technology will be crucial to imaging retinal function in the future, Prof Hüttmann predicted at the International SPECTRALIS Symposium

This noninvasive imaging tool reveals early brain pathology through the eye, promising faster and more accurate diagnoses as highlighted at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Findings presented at the Heidelberg 2025 International SPECTRALIS Symposium — And Beyond (ISS) suggest detailed structural data could better inform therapeutic targeting and monitoring.

Improved axial resolution allows clearer visualization of early atrophic changes, including iRORA vs cRORA differentiation, as shared at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

From basal laminar deposits to foveal centering, a new framework refines what clinicians see—and what they treat—in outer retinal disease, as presented at the Heidelberg 2025 International SPECTRALIS Symposium – And Beyond (ISS).

Prof Malik shared his presentation, titled "An eye on neurodegenerative diseases: Challenging the dogma," at this year's International SPECTRALIS Symposium

Prof Hogg presented a wide breadth of research at the International SPECTRALIS Symposium

Amneal Pharmaceuticals received FDA approval for its prednisolone acetate ophthalmic suspension, a steroid eye inflammation treatment referencing Allergan’s Pred Forte, with a US launch planned for Q3 2025.

Lamivudine could provide an oral option to more effectively treat DME at a lower cost to patients

Harrow expects BYQLOVI to be commercially available in the fourth quarter of 2025.

The novel preservative-free eye drop therapy for glaucoma aims to improve IOP control and patient adherence with a fixed-dose combination.

Researchers hypothesize that lamivudine was effective in the clinical trial against DME because the drug blocks the activity of inflammasomes.

A new study compared results to determine a more comprehensive understanding of the relationship between the grade of surgeon and ISBCS outcomes

ZTech-L and ZTech-P, as part of the ZTech portfolio, supports administering therapeutics in both liquid and dry powder formulations

Compared with penicillin, investigators reported no significant differences in the incidence of ophthalmologic manifestations among patients treated with ceftriaxone.

Cabozantinib is a vascular endothelial growth factor receptor tyrosine kinase inhibitor, a drug used as a therapy for several malignancies.

CLARUS 700, the advanced retinal imaging system, captures 133 degrees in a single image and up to 267 degrees with multiple images.

FDA noted that the US phase 2 trial may serve as 1 of the 2 pivotal trials required for NDA filing.

The gift will be used to treat and potentially cure eye diseases like macular degeneration and glaucoma, increase focus on basic science, and harness artificial intelligence to revolutionize vision care.

Cabozantinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, has previously been associated with hepatic and dermatologic adverse effects